Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026)

Verano Holdings' (VRNO) quarterly Total Non-Current Liabilities came in at $902.9 million in Q1 2026, up 5.02% year-on-year from $859.7 million in Q1 2025, and little changed on a QoQ basis from $899.0 million in Q4 2025.

Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Verano Holdings (VRNO) has 6 years of Total Non-Current Liabilities data on file, last reported at $902.9 million in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 5.02% year-over-year to $902.9 million in Q1 2026; TTM through Mar 2026 was $902.9 million, a 5.02% increase from a year earlier, with the FY2025 full-year figure at $899.0 million, up 7.0% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $902.9 million, roughly flat from $899.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for VRNO reached as high as $902.9 million in Q1 2026 and fell as low as $469.5 million in Q2 2022.
  • Historically, Total Non-Current Liabilities has averaged $736.3 million across 5 years, with a median of $680.7 million in 2023.
  • Across the five-year window, Total Non-Current Liabilities surged 43.17% in 2023 and retreated 4.02% in 2024, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $667.9 million in 2022, then declined by 0.21% to $666.5 million in 2023, then gained by 26.06% to $840.2 million in 2024, then gained by 7.0% to $899.0 million in 2025, then advanced by 0.44% to $902.9 million in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $902.9 million in Q1 2026, $899.0 million in Q4 2025, and $897.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Verano Holdings 2.02 Bn 1.94 Bn 98.98 Mn 902.87 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 902.87 Mn
Dec 31, 2025 898.95 Mn
Sep 30, 2025 897.85 Mn
Jun 30, 2025 868.42 Mn
Mar 31, 2025 859.73 Mn
Dec 31, 2024 840.17 Mn
Sep 30, 2024 661.59 Mn
Jun 30, 2024 657.07 Mn
Mar 31, 2024 661.13 Mn
Dec 31, 2023 666.48 Mn
Sep 30, 2023 689.32 Mn
Jun 30, 2023 672.14 Mn
Mar 31, 2023 669.11 Mn
Dec 31, 2022 667.86 Mn
Sep 30, 2022 698.54 Mn
Jun 30, 2022 469.47 Mn
Dec 31, 2021 596.33 Mn